Dermatology
| Atopic Dermatitis
Dermatology
Atopic Dermatitis

Effect of upadacitinib on cutaneous transcriptomic and systemic proteomic dysregulation in patients with moderate-to-severe atopic dermatitis

book_2 Source: EADV Congress 2022 -  Oral session
calendar_today Published on Medfyle: September 2022
import_contacts 7 min
headphones 4 min

In this medfyle

Changes in the AD transcriptome may help evaluate targeted therapies. This biomarker analysis from Heads Up shows upadacitinib improved the transcriptome to a greater extent than dupilumab.

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Expert commentary

Prof. Thomas Bieber

University Hospital fo Bonn, Germany
Christine Kühne-Center for Allergy Research and Education,
Davos, Switzerland

About this Medfyle
Read more arrow_downward Hide arrow_upward

This is a highlights summary of an oral session given at the EADV 2022 - 31st Congress and presented by:

Dr. Emma Guttman-Yassky
Icahn School of Medicine at Mount Sinai
New York, United States

The content is produced by Infomedica, the official reporting partner of EADV 2022. 

The presenting authors of the original session had no part in the creation of this conference highlights summary.


Feedback